What will be important about biosimilars market penetration will be such rules that really push prescribers and payers to go for lower priced products compared with originator products.
This makes it an attractive market for pharma, and the future looks promising – with 63 billion dollar global biologic sales products due to come off patent by 2016. The Biosimilars market will ...
CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars: On January 30, 2025, the European Medicines Agency (EMA) Committee ...
Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate ...
After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...
Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, ...
A panelist discusses how their institution evaluates biosimilars for formulary inclusion through a systematic review process ...
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback